Table 3. Univariate Analyses of Factors... | American Society of Hematology

Table 3.

Univariate Analyses of Factors Associated to TRM, Relapse, EFS for Related and Unrelated CBT

Factors	Related n = 42							Unrelated n = 60
	n	1 yr TRM		2 yr Relapse		2 yr EFS		n	1 yr TRM		2 yr Relapse		2 yr EFS
	n	%	P	%	P	%	P	n	%	P	%	P	%	P
Age
<2 yr	2	0	.04	0	.41	100	.17	14	37	.59	66	.04	24	.13
2 to 10 yr	35	31		47		39		36	64		42		22
≥10 yr	5	80		0		20		10	40		0		60
Weight
<20 kg	21	15	.008	58	.04	40	.46	28	43	.46	66	.006	21	.29
≥20 kg	21	57		5		38		32	59		4		39
CMV
Negative	20	21	.07	29	.03	56	.02	25	47	.37	43	.95	33	.39
Positive	22	48		58		25		34	56		37		28
ABO
Matched	31	38	.63	59	.07	28	.09	27	48	.39	41	.42	31	.23
Mismatched	11	28		0		72		33	56		37		29
Gender
Matched	20	22	.06	41	.75	48	.13	29	49	.80	49	.54	27	.77
Mismatched	21	49		37		33		29	51		31		35
Type
ALL	30	43	.14	42	.54	33	.34	40	57	.29	38	.66	28	.68
AML	12	18		39		58		20	42		45		32
Karyotype
Good	7	57		33		29		5	47		25		40
Intermediate	24	37	.33	44	.90	35	.62	38	49	.79	37	.39	34	.41
Poor	11	18		35		55		17	59		56		18
Relapse
On therapy	17	27	.16	67	.10	24	.72	30	55	.23	57	.16	22	.07
Off therapy	16	50		17		44		17	44		16		48
Time from diagnosis to relapse
<500 d	12	25	.28	54	.94	36	.40	29	54	.99	36	.91	30	.98
≥500 d	21	46		39		32		18	51		40		31
Disease status
Poor risk	18	58	.04	71	.02	11	.001	18	71	.07	75	.22	7	.02
Good risk	24	21		26		65		42	43		31		40
Time from last CR to CBT
<92 d	11	36	.79	0	.18	64	.49	29	56	.74	36	.69	28	.53
≥92 d	12	32		49		53		19	47		17		44
HLA^3-150
Identical	30	21		45		48		6	50		50		25
1 difference	1	100	.01	0	.43	0	.005	27	34	.07	29	.81	49	.19
2 differences	3	33		0		67		22	76		44		14
3 differences	7	82		100		0		4	25		100		25
4 differences	1	100		0		0		1	0		0		100
Cell dose
<3.7 × 10⁷/kg	23	51	.03	15	.04	39	.60	25	62	.21	14	.24	33	.78
≥3.7 × 10⁷/kg	19	16		72		39		35	44		54		28

Factors	Related n = 42							Unrelated n = 60
	n	1 yr TRM		2 yr Relapse		2 yr EFS		n	1 yr TRM		2 yr Relapse		2 yr EFS
	n	%	P	%	P	%	P	n	%	P	%	P	%	P
Age
<2 yr	2	0	.04	0	.41	100	.17	14	37	.59	66	.04	24	.13
2 to 10 yr	35	31		47		39		36	64		42		22
≥10 yr	5	80		0		20		10	40		0		60
Weight
<20 kg	21	15	.008	58	.04	40	.46	28	43	.46	66	.006	21	.29
≥20 kg	21	57		5		38		32	59		4		39
CMV
Negative	20	21	.07	29	.03	56	.02	25	47	.37	43	.95	33	.39
Positive	22	48		58		25		34	56		37		28
ABO
Matched	31	38	.63	59	.07	28	.09	27	48	.39	41	.42	31	.23
Mismatched	11	28		0		72		33	56		37		29
Gender
Matched	20	22	.06	41	.75	48	.13	29	49	.80	49	.54	27	.77
Mismatched	21	49		37		33		29	51		31		35
Type
ALL	30	43	.14	42	.54	33	.34	40	57	.29	38	.66	28	.68
AML	12	18		39		58		20	42		45		32
Karyotype
Good	7	57		33		29		5	47		25		40
Intermediate	24	37	.33	44	.90	35	.62	38	49	.79	37	.39	34	.41
Poor	11	18		35		55		17	59		56		18
Relapse
On therapy	17	27	.16	67	.10	24	.72	30	55	.23	57	.16	22	.07
Off therapy	16	50		17		44		17	44		16		48
Time from diagnosis to relapse
<500 d	12	25	.28	54	.94	36	.40	29	54	.99	36	.91	30	.98
≥500 d	21	46		39		32		18	51		40		31
Disease status
Poor risk	18	58	.04	71	.02	11	.001	18	71	.07	75	.22	7	.02
Good risk	24	21		26		65		42	43		31		40
Time from last CR to CBT
<92 d	11	36	.79	0	.18	64	.49	29	56	.74	36	.69	28	.53
≥92 d	12	32		49		53		19	47		17		44
HLA^3-150
Identical	30	21		45		48		6	50		50		25
1 difference	1	100	.01	0	.43	0	.005	27	34	.07	29	.81	49	.19
2 differences	3	33		0		67		22	76		44		14
3 differences	7	82		100		0		4	25		100		25
4 differences	1	100		0		0		1	0		0		100
Cell dose
<3.7 × 10⁷/kg	23	51	.03	15	.04	39	.60	25	62	.21	14	.24	33	.78
≥3.7 × 10⁷/kg	19	16		72		39		35	44		54		28

HLA low resolution typing for related transplants and high resolution typing for unrelated transplants.